Skip to main content
New product approved
for adults with major depressive disorder
     view press release


a potentially new treatment option for fibromyalgia.

AXS-14 (esreboxetine) is a novel, oral, investigational medicine. It is a highly selective and potent norepinephrine reuptake inhibitor.

Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine.

AXS-14 has met the primary endpoints and demonstrated positive and statistically significant results in a Phase 3 and in a Phase 2 trial for the treatment of fibromyalgia.

AXS-14 is an investigational drug not approved by the FDA and its safety and effectiveness have not been established.

clinical and regulatory

AXS-14 is currently being developed for the treatment of fibromyalgia. The product is in the preparing to submit an NDA phase of development.